L G Czaplewski

Summary

Country: UK

Publications

  1. ncbi Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants
    L G Czaplewski
    British Biotech Pharmaceuticals Ltd, Watlington Road, Oxford OX4 5LY, United Kingdom
    J Biol Chem 274:16077-84. 1999
  2. ncbi Aggregation of RANTES is responsible for its inflammatory properties. Characterization of nonaggregating, noninflammatory RANTES mutants
    V Appay
    British Biotech Pharmaceuticals Ltd, Watlington Road, Oxford OX4 5LY, United Kingdom
    J Biol Chem 274:27505-12. 1999
  3. ncbi BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties
    M G Hunter
    British Biotech Pharmaceuticals Ltd, Oxford, UK
    Blood 86:4400-8. 1995
  4. ncbi Identification and characterization of a rat macrophage inflammatory protein-1alpha receptor
    A Waller
    British Biotech Pharmaceuticals, Ltd, Oxford, UK
    J Hematother Stem Cell Res 9:703-9. 2000

Collaborators

  • B I Lord
  • Victor Appay
  • A Waller
  • M G Hunter
  • P Nayee
  • A H Gearing
  • A H Drummond
  • T M Dexter
  • S Cribbes
  • L M Wood
  • C M Heyworth
  • S Craig
  • P G Varley
  • L Bawden
  • M McCourt
  • D Brotherton
  • R M Edwards
  • P J Lewis

Detail Information

Publications4

  1. ncbi Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants
    L G Czaplewski
    British Biotech Pharmaceuticals Ltd, Watlington Road, Oxford OX4 5LY, United Kingdom
    J Biol Chem 274:16077-84. 1999
    ..This observation has important implications for potential therapeutic uses of chemokines implying that disaggregated forms may be necessary for safe clinical investigation...
  2. ncbi Aggregation of RANTES is responsible for its inflammatory properties. Characterization of nonaggregating, noninflammatory RANTES mutants
    V Appay
    British Biotech Pharmaceuticals Ltd, Watlington Road, Oxford OX4 5LY, United Kingdom
    J Biol Chem 274:27505-12. 1999
    ..Disaggregated RANTES will be a valuable tool to explore the biology of RANTES action in human immunodeficiency virus infection and in inflammatory disease...
  3. ncbi BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties
    M G Hunter
    British Biotech Pharmaceuticals Ltd, Oxford, UK
    Blood 86:4400-8. 1995
    ..The myeloprotective activity of BB-10010 was shown in a murine model of repeated chemotherapy using hydroxyurea. BB-10010 is therefore an ideal variant with which to evaluate the therapeutic potential of recombinant human MIP-1 alpha...
  4. ncbi Identification and characterization of a rat macrophage inflammatory protein-1alpha receptor
    A Waller
    British Biotech Pharmaceuticals, Ltd, Oxford, UK
    J Hematother Stem Cell Res 9:703-9. 2000
    ..Therefore, we have adopted lowercase nomenclature for the receptor until signaling is observed. This receptor and cell line may be of use in the preclinical development of CCR1 antagonists...